Status:

COMPLETED

Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/CT in Patients With Gastrointestinal Tumors and Compared With 18F-FDG PET/CT

Lead Sponsor:

The First Affiliated Hospital of Xiamen University

Conditions:

Gastric Cancer

Pancreatic Cancer

Eligibility:

All Genders

18-90 years

Phase:

NA

Brief Summary

To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in gastrointestinal tumors, and compa...

Detailed Description

Subjects with gastrointestinal tumors underwent contemporaneous 18F-AlF-FAPI and 18F-FDG PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum...

Eligibility Criteria

Inclusion

  • adult patients (aged 18 years or order);
  • patients with suspected or newly diagnosed or previously treated gastrointestinal tumors (supporting evidence may include MRI, CT, tumor markers and pathology report);
  • patients who had scheduled both 18F-FDG and 18F-AlF-FAPI PET/CT scans;
  • patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion

  • patients with non-malignant lesions;
  • patients with pregnancy;
  • the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Key Trial Info

Start Date :

June 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 31 2024

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT05430841

Start Date

June 1 2022

End Date

October 31 2024

Last Update

August 1 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The First affiliated hospital of xiamen university

Xiamen, Fujian, China, 361000